PharmaShots | Incisive News in 3 Shots

Subscribe Now

CG Oncology

CG Oncology to Highlight the P-II (CORE-001) Trial Data of Cretostimogene Grenadenorepvec Plus Keytruda for Bladder Cancer at ASCO 2024

CG Oncology to Highlight the P-II (CORE-001) Trial Data of Cretostimogene Grenadenorepvec Plus Keytruda for Bladder Cancer at ASCO...

May 27, 2024

CG Oncology’s Cretostimogene Grenadenorepvec Receives FTD and BTD from the US FDA for High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

CG Oncology’s Cretostimogene Grenadenorepvec Receives FTD and BTD from the US FDA for High-Risk BCG-Unresponsive Non-Muscle Invasi...

December 6, 2023

CG Oncology Presents Interim Results of CG0070 + Keytruda (pembrolizumab) in P-II (CORE1) Study for NMIBC Unresponsive to Bacillus Calmette-Guerin at AACR 2022

CG Oncology Presents Interim Results of CG0070 + Keytruda (pembrolizumab) in P-II (CORE1) Study for NMIBC Unresponsive to Bacillus...

April 14, 2022

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us